The Longevity Letter #3: Rapamycin passes 48‑week safety test—what it means for your clinic
Rapamycin just cleared a 48-week safety milestone, offering promising insights for clinicians exploring precision longevity protocols. From senolytic breakthroughs to AI-assisted biomarkers, discover
Elevate X Health
Precision Longevity Health
Hi ,
I’m back from a whirlwind long weekend in Taiwan—attending a wedding and checking in on my father, who’s recovering from a heart transplant (a big impetus for my work in precision longevity).
Meanwhile, the science and business innovation of longevity kept sprinting forward. Here are the latest updates for anyone building or running a precision‑longevity service line.
1. Senolytics Move From Theory → Real Outcomes
UNITY’s Phase 2b ASPIRE trial reported that a single dose of the senolytic UBX1325 produced vision gains through week 36 comparable to aflibercept in tough‑to‑treat diabetic macular edema.
Why it matters: It’s the first human evidence that selectively clearing senescent cells can durably remodel tissue—validating UNITY’s “ophthalmology‑first” path and giving clinics a clear IRB conversation starter for future senolytic trials.
Share Elevate X's updates ahead of our launch
Join the Waitlist2. Rapamycin Shows Year-Long Safety–and Surprising Benefits
The peer‑reviewed PEARL trial (48 weeks, 5–10 mg weekly) found no significant safety signals and a lean‑mass increase plus pain reduction in women on 10 mg. A quick note on dosing; this study was performed using compounded rapamycin, which about a third as bioavailable than manufacturer-grade rapamycin, meaning clinicians who want to create similar protocols may need to adjust dosing accordingly. There's discussion in the community as well about whether similar results may not have been found for male participants due to the dose being too low for an effect. Regardless, the safety outcomes are promising given prior concern about rapamycin being traditionally used as an immunosuppressant.
Clinic takeaway: Low‑dose, intermittent rapamycin is looking ever safer for properly screened adults. Start baseline DXA scans and longitudinal labs now so you can contribute real‑world data as dosing guidance tightens.
3. FDA Signals a Faster Lane for AI Devices
Two weeks ago the agency released draft guidance on AI/ML‑enabled medical devices, outlining lifecycle management and streamlined submissions.
Pair that with brand‑new data on AI‑assisted biomarker segmentation for nAMD, published just 48 hours ago, showing improved precision in tracking disease activity.
Why it matters: Regulatory clarity plus fresh clinical proof‑points = green light for integrating AI biomarkers (think biological‑age from fundus or blood) into your care pathways. We're keeping a close eye on similar developments for our own R&D.
Share our newsletter for longevity updates
Subscribe hereQuick Stat 📊
A January 2025 VA time‑motion study found clinicians spend 35‑46 % of each visit in the EHR—about 9 minutes every 24‑minute encounter. Automating just 5 of those minutes frees ≈ 167 clinician‑hours a year for a 500‑member cash‑pay panel— > four extra work‑weeks you can reinvest in deeper consults or growth.
Feature in Focus → Lab Sync
Problem our early partners flagged: re‑typing labs is killing consult time.
- Google Workspace Sync (live today) — Secure, HIPAA‑configured pull of Google Sheets and Drive PDFs straight into Elevate X's interface. We chose this integration to solve first given the potential for automating multiple workflows including scheduling and email messaging.
- LabLink (beta-build) — We're building out real‑time pipes from lab providers such as Rupa Health and Quest. Our parser auto‑maps results, flags deltas, and drafts the progress‑note table in seconds.
Early testers close the chart before the patient leaves, then spend the saved time tweaking protocols that separate precision clinics from retail longevity shops.
Founder’s Corner
“Every appointment is an N‑of‑1 trial waiting to become science. Automate the grunt work and clinicians can publish proof‑of‑impact without sacrificing revenue—or sleep.”— Hillary Lin, MD
Your Insider Perk
You’re already on the Elevate X insider list—thank you. To keep access truly curated, we’re capping the next beta cohort at just 5 clinics.
Forward this newsletter to one physician, operator, or founder you trust to raise the bar for evidence‑based longevity. By joining the waitlist, you'll unlock priority access to our precision longevity co-pilot, built with the latest agentic AI architecture.
Our inbox is open; if you have a feature request or burning problem to be solved, hit reply and share more!
Hillary Lin, MD
Co-Founder & CEO
Elevate X Health
